Clinical Trial Update from NMD Pharma: CMT Type 1 & Type 2
Автор: CMT Research Foundation
Загружено: 2026-02-19
Просмотров: 257
Описание: A live discussion with Daniel Brennan, NMD Pharma’s SVP of Corporate and Commercial Strategy. Sharing an update regarding topline results from their Phase 2a clinical study called SYNAPSE-CMT. This clinical study explored whether the new, investigational drug ignaseclant (formerly NMD670), could provide benefit adults with Charcot-Marie-Tooth disease (CMT) type 1 and type 2. The CMTRF is optimistic about what ignaseclant and the results of the clinical trail could mean for the CMT patient community.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: